Homepage
Medication Guide
How to Use Eliglustat (Cerdelga)
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor that received its first approval in the United States in 2014. As a long-acting therapeutic agent for Type 1 Gaucher disease, it provides...
504
Thursday, December 4th, 2025, 11:26
What Kind of Drug Is Eliglustat (Cerdelga)?
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor that received its first approval in the United States in 2014. As a targeted therapy for Type 1 Gaucher disease, it acts as a substrate r...
502
Thursday, December 4th, 2025, 11:21
How to Purchase Eliglustat (Cerdelga)
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor. It is specifically indicated for the long-term treatment of adult patients with Type 1 Gaucher disease who have been confirmed as CYP2D6...
502
Thursday, December 4th, 2025, 11:16
Side Effects of Pirtobrutinib
Pirtobrutinib is a novel Bruton’s Tyrosine Kinase (BTK) inhibitor. It has been approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in patients who have received at least 2 lin...
502
Thursday, December 4th, 2025, 11:14
What Are the Precautions for Pirtobrutinib Administration?
Pirtobrutinib is a kinase inhibitor. It is used to treat relapsed or refractory mantle cell lymphoma (MCL) in patients who have previously received at least two lines of systemic therapy (including a ...
500
Thursday, December 4th, 2025, 11:11
Dosage and Administration of Pirtobrutinib
Pirtobrutinib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a highly selective BTK inhibitor, it has demonstrated favorable efficacy in the treatment of...
501
Thursday, December 4th, 2025, 11:09
What Are the Indications for Pirtobrutinib?
Pirtobrutinib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a non-covalent inhibitor of Bruton's Tyrosine Kinase (BTK), it demonstrates unique advan...
500
Thursday, December 4th, 2025, 11:06
What Are the Purchase Channels for Pirtobrutinib?
Pirtobrutinib is a novel BTK kinase inhibitor. It provides a new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two lines of...
502
Thursday, December 4th, 2025, 11:00
Side Effects of Capivasertib
Capivasertib is a next-generation AKT kinase inhibitor. Used in combination with fulvestrant, it treats HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN mutations. While de...
500
Thursday, December 4th, 2025, 10:45
What Are the Precautions for Capivasertib Administration?
Capivasertib is a kinase inhibitor. It is used in combination with fulvestrant for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer harboring PIK3CA/AKT1/PTEN gene muta...
502
Thursday, December 4th, 2025, 10:42
13 / 184
1832 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved